January 22, 2017 7:43 AM ET


Company Overview of Relypsa, Inc.

Company Overview

Relypsa, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of polymeric medicines for patients with conditions that are overlooked and undertreated and can be addressed in the gastrointestinal tract primarily in the United States. The company offers Veltassa (patiromer), a non-absorbed potassium binding polymer for the treatment of hyperkalemia. It has license agreement with Vifor Fresenius Medical Care Renal Pharma Ltd. for developing and commercializing Veltassa outside the United States and Japan. The company was founded in 2007 and is headquartered in Redwood City, California. As of August 31, 2016, Relypsa, Inc. operates as a subsidiary of V...

100 Cardinal Way

Redwood City, CA 94063

United States

Founded in 2007

429 Employees



Key Executives for Relypsa, Inc.

Chief Executive Officer, President and Director
Age: 51
Chief Financial Officer, Principal Accounting Officer and Senior Vice President
Age: 44
Chief Scientific Officer and Senior Vice President
Age: 51
Chief Medical Officer and Senior Vice President
Age: 45
Chief Commercial Officer and Senior Vice President
Age: 47
Compensation as of Fiscal Year 2016.

Relypsa, Inc. Key Developments

Relypsa, Inc. Announces FDA Approves Supplemental New Drug Application for Veltassa Removing Boxed Warning Regarding Drug-Drug Interactions

Relypsa, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) with important updates to the label of Veltassa® (patiromer) for oral suspension. Veltassa’s label no longer includes a Boxed Warning regarding the separation of Veltassa and other oral medications. The updated label recommends patients take Veltassa at least 3 hours before or 3 hours after other oral medications. This information is now detailed in the dosage and administration section (Section 2) and the drug interactions section (Section 7) of the label. In addition, data from the Veltassa drug-drug interaction program has been added to the Clinical Pharmacology section of the label (Section 12).

Relypsa, Inc. Presents at Credit Suisse 25th Annual Healthcare Conference, Nov-08-2016

Relypsa, Inc. Presents at Credit Suisse 25th Annual Healthcare Conference, Nov-08-2016 . Venue: The Phoenician, 6000 East Camelback Road, Scottsdale, AZ 85251, United States. Speakers: John A. Orwin, Chief Executive Officer, President and Director.

Relypsa Files Form 15

Relypsa, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock, par value $0.001 per share under the Securities Exchange Act of 1934, as amended.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

July 21, 2016
Private Placement
April 27, 2016

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Relypsa, Inc., please visit www.relypsa.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.